Navigation Links
Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments
Date:10/28/2010

NEW YORK, Oct. 28 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented research results of once-daily INTUNIV™ (guanfacine) Extended-Release Tablets, coadministered with stimulants in children and adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who had suboptimal response to treatment with a long-acting stimulant alone.  At study end point, patients receiving INTUNIV coadministered with a stimulant had significantly reduced symptoms on the ADHD Rating Scale IV (ADHD-RS-IV) compared with those receiving placebo with a stimulant, regardless of morning or evening dosing.  These data were presented in a poster session at a major national scientific meeting of psychiatry in New York, NY.

"This study looked at patients who were taking a stable dose of a long-acting stimulant medicine but who continued to experience ADHD symptoms," said Timothy Wilens, MD, Staff in the Pediatric Psychopharmacology Unit at Massachusetts General Hospital and Associate Professor of Psychiatry at Harvard Medical School, who led the study.  "These findings provide greater insight into the use of INTUNIV when combined with a stimulant."

INTUNIV is a selective alpha-2A agonist approved for the treatment of ADHD in children and adolescents ages 6 to 17.  Efficacy was based on two pivotal studies (8 and 9 weeks in duration) of INTUNIV administered as monotherapy.  INTUNIV is indicated as an integral part of a total treatment program that may include counseling or other measures.

These data presented today were included as part of a supplemental New Drug Application (sNDA) submitted to the Food and Drug Administration (FDA) on April 28, 2010, seeking approval for INTUNIV as an ADHD
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. 52-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus
2. Repligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreichs Ataxia
3. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
4. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
5. Peoria Clinical Research Center Tests Investigational Drug to Treat Painful Menstrual Cramps
6. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
7. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
8. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
9. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
10. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
11. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... UAE (PRWEB) October 22, 2014 Grace ... science and healthcare projects, announces the addition of ... DCH to its advisory team. Dr. Siddiqui will provide ... , A graduate of University College Medical ... subsequently degreed in medicine in 2001. With further certification ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... 22, 2014 Research and Markets  has ... by Material, by Application, Geography - Global Analysis and ... Organic electronics, also called as polymer ... science which deals with small conductive molecules and electrically ... molecules and polymers are carbon based, made using synthetic ...
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... NASA clean rooms, where scientists and engineers assemble ... deep mines as unlikely places where scientists have ... species of bacteria uncovered in a recent NASA ... According to Dr. Kasthuri Venkateswaran, who led the ...
... Calif., Aug. 31 Anacor Pharmaceuticals,announced today that it ... Securities and Exchange Commission for a proposed initial public,offering ... shares in the proposed,offering are being sold by Anacor. ... Stanley & Co.,Incorporated as sole book runner, Cowen and ...
... (Nasdaq: KNDL ), a,leading, global full-service clinical ... Chief Financial Officer Karl,"Buzz" Brenkert, III will participate ... the Four Seasons in Boston, MA, September,5-7, 2007. ... at,2:40 p.m. Eastern Time. (LOGO: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO ...
Cached Biology Technology:NASA study will help stop stowaways to Mars 2Anacor Files Registration Statement for Initial Public Offering 2Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007 2
(Date:10/15/2014)... The Ebola virus is spreading rapidly and to an ... experienced in the past and the virus shows a ... been recorded before. For this reason, the German National ... of Science and Engineering, and the Union of the ... statement on the Ebola epidemic today. , In the ...
(Date:10/15/2014)... , Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market releases photos and ... Times Square on Monday October 13 th . ... David Tunnel and angel investor Mr. Chad A. Verdi ... CEO of NXT-ID thanked his investors and employees "for their work ...
(Date:10/15/2014)... 2014   Neurotechnology , a provider of ... of the VeriLook Surveillance 3.0 software development ... biometric face identification using live video streams from ... new version not only identifies faces in a ... while they are moving through the video frame. ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... www.lternet.edu, has released its new Decadal Science Plan, ... the next 10 years. Titled Integrative Science for ... Education, and Cyberinfrastructure in the U.S. Long-Term Ecological ... for research that extends the Networks foundational strength ...
... human activities are not just heating up the globe, ... soon be fatal to coral reefs, which are havens ... coastal communities. Scientists from the Carnegie Institutions Department ... dioxide emission trends continue, by mid-century 98% of present-day ...
... of life would appear to have been influenced by ... by genes from DNA into messenger-RNA (mRNA), which in ... RNA polymerase II is highly conserved through evolution, with ... and humans. Single-cell organisms were already in ...
Cached Biology News:LTER unveils a new decadal science plan 2Coral reefs unlikely to survive in acid oceans 2Evolution with a restricted number of genes 2
... Multiple solvents can be used, such as water, benzene, formamide, nitrobenzene, cyclohexane, 1,4-dioxane, p-xylene, dimethyl ... * Range: 12-position switchable: ... ... ...
Growth Medium / Media...
... samples. Operating head automatically rises at the end of determination; triple-point calibration verification; refrigerator eliminates need for ... ... ... ...
Request Info...
Biology Products: